Posted by Michael Wonder on 09 Mar 2020
Celltrion applies for European approval of Humira biosimilar
9 March 2020 - Celltrion said Monday that it applied for the European Medicine Agency’s commercialization approval of CT-P17, a Humira (adalimumab) biosimilar.
CT-P17 is a highly potent biosimilar of AbbVie’s auto-immune disease treatment Humira, a blockbuster original that recorded $19.1 billion global revenue in 2019.
If approved, the CT-P17 will be a meaningful addition to Celltrion’s portfolio for rheumatoid arthritis and inflammatory bowel disease treatment, alongside the company’s Remicade (infliximab) biosimilar Remsima. The TNF-alpha inhibitor market these drugs set out to target is estimated to be 50 trillion won ($41.7 billion) in size, globally.
